CTRI/2024/03/064225尚未招募2 期
Clinical validation of safety and effectiveness of Zipitrit skin cream (Batch No. ZP-01) in the management of skin fungal infection and eczema. - NI
M. N. Pharmaceuticals0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age group between 18 to 65 years old, both inclusive
- •2. Confirmed diagnosis of skin fungal infection
- •3. No systemic antifungal treatment within the previous two weeks
- •4. No use of topical antifungal agents within the previous seven days
- •5. No history of allergy to components of the study medication
- •6. Subjects ready to take injection TT before application of study drug
- •Inclusion criteria for eczema:
- •1. Patients of either sex in the age group between 18 to 65 years both inclusive;
- •2. IGA score of 2 or 3 (mild or moderate) during screening and baseline;
- •3. BSA of AD involvement of 4-12%;
- •4. EASI of 5-20 Clinical diagnoses of Atopic Dermatitis (as defined by Hanifin and Rajka criteria);
- •5. Atopic Dermatitis should be present for at least three months with stable disease for more than or equal to 1 month prior to screening.
- •6. Subjects ready to take injection TT before application of study drug
排除标准
- •1. Pregnant or lactating women or women of child bearing positive urine pregnancy test at screening. All subjects agree to use an adequate contraceptive method throughout the study;
- •2. Use of biologic therapy within 12 weeks;
- •3. Regular use of tanning booth within 4 weeks;
- •4. Concomitant dermatologic (e.g. irritant contact dermatitis, allergic contact dermatitis, psoriasis, etc.) or other medical condition(s) which may interfere with study assessments;
- •5. Any other comorbid condition which is not on stable prescription for last 3 months.
- •6. Subjects who are using any concomitant medications that in the investigators opinion, could affect the subjects atopic dermatitis (e.g. Antihistamines) Subjects using such medications and have been stable on treatment for at least one month prior to visit 2 (Day 1 of IP) and no changes to these medications are planned during study may be included in the study at the investigators discretion;
- •7. Abnormal renal function (defined as serum creatinine more than 1.5xULN) or abnormal liver function (defined as any transaminases more than 2xULN);
- •8. Known hypersensitivity to any of the components of the study drug;
- •9. Known or suspected history of alcohol or drug abuse;
- •10. Subjects with a history of human immunodeficiency virus (HIV) as determined by medical history;
- •11. Subjects who are receiving any investigational drug or who participated in a similar clinical trial with an investigational product within the last 3 months;
- •12. Any other condition as per discretion of investigator would interfere with the clinical evaluations.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the safety and efficacy of the product in subjects experiencing hair lossCTRI/2018/03/012303Dabur Research Foundation
已完成
不适用
Clinical evaluation of the efficacy and safety of Hochuekkito for fatigue in patients with myeloproliferative neoplasmsmyeloproliferative neoplasmsJPRN-UMIN000031519Department of Hematology, Juntendo University School of Medicine110
招募中
1 期
Clinical evaluation of the efficacy and safety of Huayu Tongbi Fomular on rheumatoid arthritisRheumatoid ArthritisITMCTR2024000092Guangdong Provincial Hospital of Chinese Medicine
已完成
3 期
Clinical evaluation of the safety and effectiveness of Excilor 2-in-1 Wart Treatment in the treatment of warts on the hands and feetISRCTN39469406Medical Brands66
未知
2 期
Clinical evaluation of the efficacy and safety of the guideline of oral ingestion of NaCl for children with ileostomyileostomyJPRN-UMIN000016711Division of Pediatric Surgery, Department of Surgery, Kobe University Graduate School of Medicine30